PSVT involves episodes of a faster-than-normal heart rate, often with symptoms resembling anxiety attacks, and while uncomfortable, it’s typically not life threatening. Diagnosis of PSVT typically ...

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...

Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved CARDAMYST, the first nasal spray that patients can self-administer to treat ...

MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...

MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first ...